Skip to main content
Download PDF

Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?

Infectious Agents and Cancer volume 11, Article number: 23 (2016) Cite this article

Abstract

Hepatitis C Virus (HCV) causes chronic infection and represents a global health burden. To date, there is no licensed vaccine for HCV. The high viral replication rate and the existence of several HCV genotypes and quasispecies hamper the development of an effective universal vaccine. In this regard, the current HCV vaccine candidates show genotype-specific protection or narrow cross reactivity against other genotypes. Importantly, HCV spontaneous clearance occurs in 15–50 % of infected subjects, indicating that natural resistance to chronic infection exists. This phenomenon was demonstrated among humans and chimpanzees and continues to motivate researchers attempting to develop an effective HCV vaccine. However, what constitutes a protective immune response or correlate of protection against HCV infection is still vague. Additionally, the mechanisms behind successful HCV clearance suggest the coordination of several arms of the immune system, with cell-mediated immunity (CMI) playing a crucial role in this process. By contrast, although neutralizing antibodies have been identified, they are isolate-specific and poorly correlate with viral clearance. Antigen-specific CD4 T cells, instead, correlate with transient decline in HCV viremia and long-lasting control of the infection. Unfortunately, HCV has been very successful in evading host immune mechanisms, leading to complications such as liver fibrosis, cirrhosis and hepatocellular carcinoma. Interestingly, CMI to HCV antigens were shown among exposed individuals without viremia or seroconversion, suggesting the clearance of prior HCV infection(s). These individuals include family members living with HCV-infected subjects, healthcare workers, IV drug users, and sexual contacts. The correlates of protection could be closely monitored among these individuals. This review provides a summary of HCV-specific immune responses in general and of CMI in particular in these cohorts. The importance of these CMI responses are discussed.

Background

Hepatitis C virus (HCV) infection is a global health burden. Nearly 185 million subjects (~3 %) of the world’s population are affected by this virus. Liver cirrhosis, progressing liver disease, and hepatocellular carcinoma (HCC) are common complications of chronic HCV infection [1, 2]. Primary infections with HCV are usually asymptomatic [3], and the majority of cases develop chronic infection. Approximately 15–50 % of infected individuals undergo spontaneous viral clearance [4]. Figure 1 shows the possible outcomes of HCV infection. Viral and host factors such as gender, coinfections, and genetics are known to affect the likelihood of clearance or persistence [5]. Figure 2 shows a summary of the factors contributing to the different outcomes of HCV infection. For example, interleukin 28B (IL28B, also known as interferon lambda 3) single nucleotide polymorphisms (SNP) have been used as predictors of viral clearance with and without therapy [6–8]. In this regard, infected patients with the IL28B.rs12979860 CC “favorable” allele are more likely to spontaneously clear HCV infection and respond more favorably to interferon (IFN)-α treatment [6–8]. Natural protective immunity against HCV has also been proven in both humans [9, 10] and chimpanzees [11]. Importantly, host-specific cell-mediated immunity (CMI) plays an essential role in the control of HCV infection [12–14].

Fig. 1
figure1

Outcome of HCV infection. Different outcomes of HCV infection and the different possibilities are shown

Full size image
Fig. 2
figure2

Factors affecting HCV natural history. Host factors are shown in the upper part of the figure and viral factors are shown in the lower part of the figure. Coinfections and comorbidities also contribute to the outcome of infection

Full size image

New vaccine strategies may benefit from targeting the generation of potent high-avidity CD8 T-cell responses which can clear virus-infected cells at mucosal surfaces. Such T-cell responses could potentially prevent mucosal transmission and significantly restrict the development of chronic HCV infection. Importantly, HCV-specific memory CD4 and CD8 T cells were shown to persist for approximately 20 years after viral clearance among humans [15] and also up to 7 years among chimpanzees [13]. The mechanisms behind this phenomenon and how memory responses are maintained are not well understood. Knowledge of factors that affect the differentiation of long-lived effector and central memory cells are important for the development of an effective T-cell vaccine [16].

Our current knowledge of HCV spontaneous clearance is incomplete. However, natural resistance to infection exists and continues to provide optimism to researchers attempting to develop effective HCV vaccines [17, 18]. The high viral production rate and the existence of seven different HCV genotypes and quasi-species has hampered the design of an effective universal vaccine. Several other factors also contribute to the lack of an effective HCV vaccine until now. Figure 3 summarizes the known factors that contribute to the difficulties of producing an effective HCV vaccine including the shortage of funds for vaccine studies, the modest interest of pharmaceutical companies and lack of a small and convenient animal model. All these factors contribute to the failure in the development of an effective universal vaccine against HCV. On the other hand, there are great advances in the development of newly direct acting antivirals (DAAs) for the treatment of HCV infection with high cure rates. However, due to their high cost, there is a limited access to these new drugs in many parts of the world, reviewed elsewhere [19]. To this end, there is a great need for an effective pan- genotypic HCV vaccine.

Fig. 3
figure3

Causes of HCV vaccine failures

Full size image

Although HCV neutralizing antibodies have been identified, these antibodies are isolate-specific and do not correlate well with viral clearance [20]. In the absence of antibodies to HCV (anti-HCV) or detectable viremia, HCV-specific CMI may represent the sole host biomarker of exposure to this virus and may offer a protective mechanism against chronic HCV infection [10]. In this regard, what constitutes a protective immune response or correlate of protection against HCV infection is still vague. HCV-specific CMI was shown in exposed uninfected subjects [21–29] without viremia or seroconversion. This was documented among subjects such as family members living with two or more HCV infected subjects [24], sexual partners of acute HCV subjects [27], intravenous drug users (IVDU) [25, 26] and healthcare workers (HCW) [28, 29]. Interestingly, HCV transmission from seronegative blood donors was suggested to occur via cellular blood products [30]. The above data suggest that host immune responses likely determine the course of HCV infection. It may be possible to define the protective nature of HCV-specific CMI responses among these individuals, and whether these responses can be replicated by a vaccine.

Review

Innate immune responses to HCV infection

Similar to many viral infections, natural and adaptive immune responses are essential in controlling HCV infection. Hepatic innate immune reactions are linked to natural killer (NK) cells, NKT cells, dendritic cells, Kupffer cells and a quick IFN response mediated by infected hepatocytes. NK and NKT cells lyse infected cells by releasing granzymes and perforin. Additionally, these cells produce huge amounts of type-II IFN (represented by IFN-γ) and tumor necrosis factor alpha (TNF-α). HCV replication cycle leads to the assembly of double stranded RNA (dsRNA) intermediates that can trigger the expression of type-I IFN genes. In this regard, the host cells identify dsRNA through the pattern recognition receptors know as Toll-like receptor 3 (TLR-3) [31]. Recognition of dsRNA by TLR-3 leads to the activation of interferon regulatory factor 3 (IRF-3). IRF-3 induces the expression of IFN-β and interferon-stimulated genes (ISGs). IFNs act against HCV replication in host cells and protect the uninfected adjacent cells from infection with HCV by inducing the expression ISGs. In this regard, the role of TLR-3 in viral infections has been shown in knock-out mice that were unable to mount a response to measles virus infection [32]. Also, TLR-3 has been shown to mediate innate immune responses against HCV infection [33].

Early defense against viral infection requires the stimulation of type-I IFN, IFN-α and IFN-β. Mice that lack IFN-α and IFN-β fail in resolving HCV infection [34]. Additionally, genetic defects in Signal Transducers and Activators of Transcription-1 (STAT-1), which is involved in the IFN signaling cascade, also result in death of humans from viral disease(s) at an early age [35]. Among chimpanzees with acute HCV infection, type-I IFN induced the expression of dsRNA-dependent protein kinase R (PKR), 2’-5’ oligoadenylate synthetase (OAS) and Mx genes. These factors have an essential part in inhibiting HCV replication and inducing apoptosis of infected hepatocytes [36]. NK cells were, also, shown to have an essential part in eliminating HCV without measurable T cell responses in chimpanzees [37].

Cellular immune response to HCV infection

Following acute infection with HCV, 15–50 % of infected people will spontaneously clear their infection [38]. Several studies suggest that successful viral clearance depends on the coordination of multiple arms of the immune system. Natural and specific immune responses play an essential part in this process, which has been reviewed elsewhere [39]. Vigorous and broad adaptive immune responses have been identified in acutely infected individuals and these responses endure among those who clear the virus. By contrast, persistent infection correlates with weak, often unnoticeable T-cell responses [40].

The adaptive immune response includes two major types of effector mechanisms: cellular responses comprising CD4 T helper (Th) cells and cytotoxic CD8 T lymphocytes (CTL); and humoral responses consisting of antibodies produced by HCV-specific B cells. Recognition of a specific viral epitope/protein is required for both adaptive immune effector mechanisms, which can target any HCV protein. However, only some B cell epitopes localized on the viral envelope or capsid proteins can induce HCV neutralizing antibodies and efficiently prevent the binding and entry of the virus, i.e., prevent HCV infection. Activated dendritic cells can present HCV antigens to specific Th cells that respond by proliferation and production of cytokines such as interleukin (IL)-2, IFN-γ or IL-4. Th cell activation and cytokine production is required for the development of CTL. Ideally, stimulated CTL found in the liver will lyse HCV-infected liver cells by cytolytic and non-cytolytic mechanisms [41].

Th and CTL are essential for the control of HCV infection in vivo. In this regard, the presence of strong T cell responses to the virus is a common characteristic among patients who clear their acute HCV infection. However, strong CD4 and CD8 responses may also occur in those who go on to chronic HCV infection. T cell responses are usually weak among HCV chronic carriers. The part played by the HCV-specific T cell response in controlling HCV infection is reinforced by several observations. First, the appearance of HCV-specific T cells in primary infection coincides with the decline in HCV viral load. Additionally, intrahepatic virus-specific CTL responses correlate with HCV clearance and with hepatic inflammatory response [42]. Second, a strong association between certain Class I and Class II alleles of human leukocytic antigen (HLA) and clearance of HCV infection has been reported. In this regard, HLA Class-I A3 and B27 alleles were shown to associate with protection and HCV clearance mediated by a response to dominant CD8 T cell epitopes [43]. Third, studies in chimpanzees demonstrated that T cell responses were essential for the HCV clearance/persistence process [12, 13].

Although HCV-specific T-cells can be more numerous in the peripheral blood mononuclear cells (PBMCs) of chronic patients than in recovered subjects, the T-cells in chronic subjects display a reduced proliferative response. T-cell lines derived from chronic HCV patients also displayed lower HCV-specific cytotoxicity when compared with cell lines derived from recovered subjects. Ex vivo IFN-γ production and the proliferation of HCV-specific cells were also defective among chronic patients. This defect could not be reversed by in vitro stimulation with IL-2 and HCV peptides. Additionally, the impairment of cytokine synthesis, cytotoxic function and HCV-specific T cell proliferation among viremic patients was associated with weak in vitro Th responses [44]. The highest frequency of HCV-specific response measured by IFN-γ Enzyme-linked immunospot (ELISPOT) assay were found within the first 8 weeks following diagnosis of HCV infection [44]. Moreover, subjects who spontaneously cleared their acute infection had a greater and broader HCV-specific T cell response when compared to their counterparts who developed chronic infection. Importantly, subjects with chronic HCV infection failed to sustain these responses and their CMI responses dropped to undetectable levels only 1 year after diagnosis of acute infection. By contrast, subjects who spontaneously resolved their infection had detectable HCV-specific T cell responses, although reduced in magnitude, up to 12 months after diagnosis of acute infection. Antigen-specific IFN-γ production by CD8 T cells declined more quickly during acute HCV-infection among subjects who went on to chronic course of the disease compared with their spontaneous resolution counterparts. Also, the extent and breadth of CD8 T cell responses acted similarly [45].

There is a need for comparative studies of the HCV-specific memory T cells responses induced by natural infection and by treatment. The part played by the immune system in controlling the outcome of HCV therapy is debatable with reports showing an enhanced [46, 47], unaffected or declining [48, 49] immune response among individuals responding to IFN-based therapy. In this regard, treatment of HCV infection at early stages could rescue long-lived HCV-specific memory T cells [50–52]. Importantly, IFN-α therapy has been shown to rescue polyfunctional HCV-specific CTL; which persisted for up to one year after therapy discontinuation [52]. On the other hand, there are limited data examining the dynamics of HCV-specific CMI responses after treatment with the new DAAs. In this regard, HCV-specific CTL were of narrow specificity among chronic HCV-infected chimpanzees and were stable over time after successful treatment with two DAAs [53].

Role of CD4 T cells

CD4 T cells deliver essential “help” for innate, cellular and humoral immunity. T helper cells activate antigen presenting cells, provide costimulatory signals for B cells, and prime and sustain CTL responses. HCV-specific Th cells correlate with transient and long-lived viral control [54–56]. Viral clearance and liver inflammation is usually synchronous with the buildup of HCV-specific Th and CTL within 8–14 weeks following infection. Several reports have revealed the presence of strong Th responses in spontaneously resolving HCV infections [42, 57, 58]. In contrast to the poor and narrow responses shown in those with chronic HCV, a strong, broad, and Th1-biased Th response was found in subjects with self-limited infection [59]. PBMCs isolated from subjects with self-limited HCV infection showed a Th1 cytokine profile, while those from chronic subjects displayed a Th2 profile. This suggests that Th1 and not Th2 responses are associated with a successful control of the virus in the early phase of infection [60–63]. Additionally, serum levels of Th2 cytokines are increased in chronic HCV infection and decrease during IFN-α therapy [64]. The extent and specificity of Th responses also seem to be essential for the control of HCV infection. In this regard, vigorous and multi-specific T cell responses and a sustained proliferation ability in response to HCV antigens are dependable measures of a protective CMI during acute infection [44]. T cells from subjects with spontaneously resolving HCV infection recognized a mean of 10 out of 37 identified HCV epitopes. On the other hand, those from patients with HCV persistence recognized only one epitope at max [65]. Circulating HCV-specific CD4 T cells from spontaneous clearance subjects simultaneously targeted 4-14 epitopes in the structural and non-structural HCV proteins for up to several years after RNA disappearance from the serum [65]. In summary, the above reports show that strong, broad, and Th1- biased responses were identified in spontaneous clearance subjects while poor and narrow responses were found among those who developed chronic infection [59, 66].

Role of CD8 T cells

The effector functions of CTL include two overlapping mechanisms: the killing of target cells and the non-cytolytic production of antiviral cytokines. An IFN-γ-mediated non-cytolytic pathway facilitates viral elimination, with >95 % of HCV replication inhibition happening at a low effector to target ratio [67]. Reports from animal studies, also, showed that CTL migrate to the liver and contribute to controlling HCV infection. The buildup of virus-specific CTL in the liver synchronizes with increased liver enzyme levels and with a transient decline in serum HCV-RNA levels [54, 68]. Like Th responses, the major player of spontaneously resolved HCV infection is a broad and multi-specific CTL response [42, 69–71]. Contrasting this observation, CTL responses are weak or target fewer epitopes in subjects having chronic infections [42, 66, 72].

Role of T regulatory cells in HCV infection

Regulatory T (Treg) cells are a subpopulation of T-cells that play an essential role in sustaining immune homeostasis and the balance between tissue damage and immune protection. Treg cells were proposed as a possible mechanism for controlling HCV-specific responses [73–75]. Chronic HCV cases have an increased frequency of Treg cells compared to controls and the Treg cells negatively correlated with the degree of inflammation [76–78]. The higher frequency of Treg cells may also explain the weak HCV-specific T-cell responses in chronic HCV patients [79]. There is also some evidence that chronic HCV patients may harbour more Treg cells in their peripheral circulation [80] and in the liver than those who are uninfected [81]. Thus, Treg cells appear to assist in the maintenance of chronic infection by inhibiting anti-HCV responses and, therefore, attenuating the intrahepatic tissue-damaging response to infection [79, 82].

CMI responses without viremia or seroconversion in high risk subjects

  1. 1.

    Health care workers (HCW)

HCW are at an increased risk of HCV infection during their work [83, 84]. The risk of getting HCV infection from a contaminated needle is estimated at 0–5 %, or approximately 10-times higher than the risk of HIV infection via a comparable event [85, 86]. In general, the occupational risk of acquiring HCV infection by a surgeon is below 0.03 %/year. This is true even when the surgeon serves subjects with a high prevalence of HCV infection [87]. The probability of HCV infection is likely dependent on several features including viral load, time and mode of injury. However, there is no scoring system for the assessment of the risk of HCV infection after occupational exposure [28].

The detection of both anti-HCV antibodies and/or HCV-RNA are usually used for the clinical determination of HCV infection. Anti-HCV seropositivity in the absence of HCV-RNA indicates past HCV infection. Importantly, HCV-specific T cell responses were documented among individuals with self-limited HCV infection [42, 58, 65]. Additionally, HCV-specific T cell responses were reported among seronegative, aviremic subjects [21, 24, 25, 88, 89]. These studies detected HCV-specific T cells that reacted with different HCV proteins by the secretion of cytokines such as IFN-γ.

Transient viremia without HCV-antibody seroconversion was proposed as an explanation for the low incidence of new HCV infections among HCW [90] and the clearance of infection among other populations supposedly exposed to low levels of HCV [23, 24, 26–28, 88, 91–93]. More than 50 % of 52 seronegative, aviremic HCW had strong HCV multi-specific CMI responses suggesting clearance of low level HCV infections. These HCW were at a high risk of HCV infection by providing healthcare to a high HCV prevalence patient cohort [29]. These responses could arise from transient infection(s) with low titers of HCV-RNA that did not induce the production of anti-HCV, as reported among humans [22, 93, 94] and chimpanzees [37, 95]. The above data suggest that relying only on the detection of HCV antibodies to identify past exposure to the virus can lead to a substantial underestimation of prior exposure to the virus especially in endemic countries or among high-risk populations. Unfortunately, the protective nature of these responses and whether they protect these HCW are difficult to prove in humans. This difficulty can be ascribed to safety and ethical issues regarding the challenge of humans with live viruses.

Interestingly, a recent trial in four monkeys suggested that exposures to sub-infectious doses of HCV actually suppresses T cell responses upon subsequent acute infection [96]. On the other hand, brief low viremia had been documented in one HCW. This HCW remained seronegative and aviremic for more than a year of follow-up after transient viremia [90]. A similar observation was also documented among other HCW in Egypt [97, 98]. These data suggest the exposure to and clearance of HCV infection without antibody seroconversion. These seronegative, aviremic HCW are frequently exposed to HCV through occupational exposure. The CMI responses found among these HCW may protect them from HCV infection. An analogous phenomenon was documented in IVDU who cleared primary HCV infections and were protected against consequent exposure to HCV. This protection was largely due to T cell responses [10]. The above data demonstrate HCV-specific T-cell responses in exposed seronegative, aviremic individuals [21–27, 99] including HCW in Europe [28, 89] and Egypt [29, 100] and seem to be in a clear contrast to the trial performed in monkeys [96]. If these CMI responses protect these individuals, they will certainly impact the plans for HCV vaccine development, the determination of past-exposure to the virus and disease burden in different communities.

Evidence of HCV-specific T-cells producing IFN-γ was shown among HCWs caring for chronic HCV patients without any documented needle stick incidents [89]. HCV-specific T-cell secretion of IFN-γ was determined for pooled HCV peptides from the core region in 10 healthy aviremic HCWs with ≥7 years of healthcare experience, and 30 HCV chronic subjects. Patients with chronic HCV infection had a lower frequency of IFN-γ spot forming cells (SFCs) than the HCW. Physicians and nurses could have some exposure to HCV antigens that induce IFN-γ production by T-cells regardless of the prophylactic precautions undertaken while caring for chronic HCV patients. This could be related to continuous exposure of the immune system to HCV antigens. The exact route of exposure to/transmission of HCV infection in these individuals that leads to activation of T cells is mysterious and remains a subject of dispute [21, 27]. These routes may include constant exposure to the virus as previously suggested [21], perhaps via skin micro-lesions or an unprotected mucosa [101, 102], which happens during daily patient care. Although these HCW had regular laboratory monitoring, unreported or under estimated needle stick injuries cannot be excluded as a source of occupational exposure to HCV [103]. Other routes of transmission are likely present among immunocompromised and immunocompetent subjects. This was shown in hospitalized cancer patients without a known infection risk who were diagnosed positive for HCV antibodies and RNA [101, 104, 105].

  1. 2.

    Household contacts

Several studies reported HCV-specific CMI without viremia or seroconversion among household contacts. In one study, CMI was examined in persons exposed to HCV without evidence of HCV infection. These persons were living in a rural community in Egypt; where anti-HCV prevalence was 24 %. Thirteen of 71 (18 %) seronegative subjects with a high-risk exposure to HCV (living with ≥2 HCV-infected patients) and only one of 35 (2.9 %) seronegative low-risk subjects (no HCV-infected subjects living in the household) had detectable CMI [24]. The authors speculated that the subjects who were seronegative and showed CMI-positive responses had a transient very mild infection, probably due to exposure to low-dose(s) of the virus which was subsequently cleared. The presence of a prior HCV infection is supported by the fact that the majority of the detected responses were to non-structural HCV proteins; which is an indication of HCV replication within these subjects. Additionally, a substantial proportion of HCV-seronegative aviremic Egyptian children at risk of infection developed broad HCV-specific CMI. These responses were suggested as a possible protective mechanism in these children against the development of chronic infection [88]. Moreover, strong HCV-specific CMI responses were demonstrated among seronegative, aviremic children born to mothers infected with HCV 3–8 years after birth [99]. The children with transient viremia after birth had the strongest IFN-γ responses to HCV antigens, particularly the NS3/NS4 antigens, with up to 80 % responding to more than one HCV antigen. In another study, CTL responses against both the structural and non-structural HCV epitopes were detected in 24.1 % of healthy family members who were constantly exposed to chronic HCV persons (18). A similar phenomenon was reported among sex-workers repeatedly exposed to human immunodeficiency virus (HIV), without detectable viremia or antibodies. These sex workers developed strong HIV-specific CMI responses against HIV-1 antigens [106]. HIV-specific CMI was suggested as a protective mechanism in these subjects against HIV-infection, potentially leading to a quick control of the virus prior to the development of antibody responses. Similarly, some household contacts of HCV-infected patients or IVDU with high risk exposures to HCV were shown not to develop apparent infection despite repeated exposure to HCV [107].

  1. 3.

    Sexual contacts and spouses

HCV-specific CMI responses in seronegative sexual partners of chronic HCV patients was examined [92]. A positive HCV-specific CMI response was documented in the PBMCs of four subjects with occult HCV infection without the detection of HCV antibodies. The authors suggested that these CMI responses are biomarkers for prior exposure and recovery from HCV, and ongoing occult infection [92]. Sexual contacts of acute HCV patients were tested with a set of 18 Class-I-restricted peptide antigens and recombinant genotype 1 proteins [27]. A substantial number of exposed subjects who remained persistently aviremic and antibody negative developed both Th- and CTL-restricted responses which were similar in breadth and strength to that of subjects with primary and self-limited HCV infections.

HCV-specific CMI against the core and NS3 proteins of HCV genotype 1 were characterized in 32 seronegative, aviremic individuals without risk of exposure to HCV, 33 exposed seronegative, aviremic individuals and 20 uninfected individuals living with chronic HCV patients [108]. Twenty percent of apparently uninfected subjects had measurable HCV-specific CMI. This frequency is higher than prior estimates of HCV prevalence in developed countries. These data are consistent with spontaneously cleared primary HCV infections or infection that remained undetectable by traditional testing methods.

  1. 4.

    IVDU and prisoners

High-risk prisoners showed HCV-specific immune response without seroconversion and may have a higher probability of HCV clearance [22]. The majority of 40 high risk seronegative, aviremic long-term IVDU had HCV-specific CMI responses [109]. Fifty eight percent of exposed uninfected IVDU produced IFN-γ in response to HCV antigens compared with only 19 % of 21 control subjects. These responses were broad and targeted several HCV proteins, eliminating cross-reactivity to other antigens as a reason for these responses. These responses may denote an imprint for HCV exposure without viremia or antibody seroconversion. The same group later demonstrated weak IFN-γ responses to both structural and non-structural HCV antigens that were significantly higher among exposed uninfected IVDU compared to healthy controls. Among exposed seronegative, aviremic cases, individuals who were not in rehabilitation demonstrated a significantly higher frequency of IFN-γ producing cells in response to HCV antigens when compared with those who stopped injections [110]. Ongoing injecting behavior in the community or in prison was suggested as a primer for these T-cell responses. Moreover, upon longitudinal follow-up, exposed uninfected subjects continuing to inject drugs were more likely to maintain a detectable IFN-γ response when compared with those who stopped injections. It was suggested that continued drug injection is crucial for maintaining HCV-specific CMI, and that these responses are lost within months of stopping injections [110]. Similar reports documented broad HCV-specific T-cell responses among high-risk, seronegative aviremic IVDU [23, 25, 26].

  1. 5.

    Hemodialysis patients

The HCV-specific T-cell functional profile was examined among high-risk seronegative, aviremic hemodialysis patients [111]. Of seventy seven hemodialysis seronegative, aviremic patients, 11.3 % displayed HCV-specific CMI responses. Occult HCV infection was not a cause of this CMI response as proven by nested RT-PCR. Interestingly, based on the cytokine profile, two unique memory T cell populations were found in these patients. These included a polyfunctional population and another population with a dominant TNFα production [111].

Theories behind the existence of CMI responses without viremia or seroconversion

There are multiple possibilities for the development of T cell responses in seronegative, aviremic subjects. These include occult HCV infection with little viral replication [112, 113], cross-reactivity to heterologous epitopes [114, 115], brief viral replication that does not lead to antibody seroconversion [22, 95] and the loss of anti-HCV antibodies following clearance of the virus [15]. However, it is not clear why only HCV-specific T cells, but not B cells, are primed in seronegative, aviremic individuals.

The existence of antigen-specific cellular responses in some seronegative subjects may be explained by the presence of cross-reactive T-cells responding to antigens from unrelated organisms. In this regard, cross-reactive Th cells against epitopes of diverse herpes viruses was reported among humans [116]. Additionally, another study reported the presence of cross-reactive CTL responses between influenza A and HCV [115]. The existence of a few HCV-peptide specific T cells among humans does not necessarily indicate previous exposure to HCV. Also, cross-reactivity with other infectious agents can certainly affect the overall profile of HCV-specific T cells [117]. In this regard, the viremia level and HCV-specific immune responses were examined following viral inoculation of chimpanzees [95]. Infective HCV doses of 1–10 RNA (+) virions induced detectable CMI responses without viremia or seroconversion [95]. Another study also suggested that pre-existing CMI responses led to a more rapid expansion of adaptive immune responses upon subsequent exposure to infectious doses of HCV and a reduced frequency of chronic hepatitis [118]. Importantly, cross reactivity alone can not explain the HCV-multi-specific responses reported among many HCW [29].

Summary

HCV spontaneous clearance remains poorly understood. However, natural protective immunity against the virus was documented in humans and chimpanzees. Host-specific CMI responses seem to have an essential role in this process. The high viral replication rate and the existence of seven HCV genotypes and quasispecies hamper the development of a universally effective vaccine. Several other factors also contribute to the unavailability of an effective HCV vaccine. Although neutralizing antibodies have been identified, they are isolate-specific and poorly correlate with viral clearance. By contrast, antigen-specific Th cells correlated with transient HCV viremia and long-lasting viral control. Vigorous, broad, and Th1-biased responses were identified among those individuals that resolve HCV infection, contrasting with the weak and narrow responses found among chronic subjects.

In the absence of anti-HCV antibodies or detectable viremia, CMI may represent the sole marker of host contact with HCV and may offer a protective mechanism against chronic hepatitis caused by this virus. HCV-specific CMI was documented among exposed subjects without viremia or seroconversion in several populations e.g., HCW, family contacts, prisoners, sexual partners, and IVDU. These data suggest the exposure to and clearance of HCV infection without seroconversion. Although direct challenge experiments cannot be performed in humans, it is possible that long-lasting seronegative persistence in fertile discordant couples will be able to prove, in the near future, the multiple exposure and the immune-protection of the seronegative partners as well as the part played by the immune response in protection from HCV infection. Further support will be provided by the seronegative, aviremic HCW constantly exposed to HCV antigens. The CMI responses mounted in these subjects can play a crucial role in their protection from HCV infection. An equivalent phenomenon is present among IVDUs who spontaneously resolve a primary HCV infection and are resistant to secondary HCV exposures. This protection correlates well with CMI responses.

Identification of host protective immune responses in subjects who spontaneously clear their HCV infection, and the longevity, magnitude, and breadth of the response; particularly in seronegative, aviremic subjects; is essential for the detection of prior exposure to HCV, understanding its natural history, and undertaking measures for its prevention. If these responses are protective, then similar CMI responses need to be simulated by future HCV vaccines. Unfortunately, the protective nature of these responses and whether those HCV-specific T cells in these seronegative, aviremic groups were able to induce viral clearance are difficult to prove in humans. Correlates of protection could be closely monitored among these seronegative, aviremic cohorts.

Conclusions

To date, there is no licensed HCV vaccine. The mechanisms behind successful HCV clearance suggest the coordination of multiple arms of the immune system, with CMI playing an essential role in this process. HCV-specific CMI has been reported among several high risk subjects without viremia or seroconversion suggesting clearance of prior infection(s) with HCV. Further studies are needed to examine the longevity of HCV-specific CMI responses in seronegative, aviremic subjects; particularly HCW; and to determine the dominant epitopes in the responding antigens. It may be possible to define the protective nature of HCV-specific CMI responses in humans, and whether these responses can be replicated by a vaccine.

Abbreviations

Anti-HCV:

antibodies to hepatitis C virus

CMI:

cell-mediated immunity

CTL:

cytotoxic T lymphocyte

DAAs:

direct acting antivirals

dsRNA:

double stranded RNA

ELISpot:

enzyme-linked immunospot assay

HCC:

hepatocellular carcinoma

HCV:

hepatitis C Virus

HCW:

healthcare workers

HIV:

human immunodeficiency virus

IFN:

interferon

IL:

interleukin

IRF-3:

interferon regulatory factor 3

ISGs:

interferon-stimulated genes

IVDU:

intravenous drug users

NK:

natural killer

OAS:

2’-5’ oligoadenylate synthetase

PKR:

protein kinase R

SFCs:

spot forming cells

SNP:

single nucleotide polymorphism

STAT:

signal transducers and activators of transcription

Th:

T helper

TLR-3:

toll like receptor 3

TNFα:

tumor necrosis factor α

Treg :

regulatory T cells

References

  1. 1.

    Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26(3 Suppl 1):34S–8.

    PubMed  Article  Google Scholar 

  2. 2.

    Lauer GaW B. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.

    Article  Google Scholar 

  3. 3.

    Alter H. Discovery of non-A, non-B hepatitis and identification of its etiology. Am J Med. 1999;107(6B):16S–20.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46. doi:10.1053/jhep.2002.36806.

    PubMed  Article  Google Scholar 

  5. 5.

    Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284(4):450–6.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801. doi:10.1038/nature08463.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet. 2002;359(9316):1478–83. doi:10.1016/S0140-6736(02)08435-0.

    PubMed  Article  Google Scholar 

  10. 10.

    Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138(1):315–24. doi:10.1053/j.gastro.2009.09.017.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Bassett SE, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel GR, et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 2001;33(6):1479–87. doi:10.1053/jhep.2001.24371.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302(5645):659–62. doi:10.1126/science.1088774.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003;197(12):1645–55. doi:10.1084/jem.20030239.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946–52. doi:10.1038/nature04079.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med. 2000;6(5):578–82. doi:10.1038/75063.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Ahlers JD, Belyakov IM. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood. 2010;115(9):1678–89. doi:10.1182/blood-2009-06-227546.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev. 2011;239(1):99–108. doi:10.1111/j.1600-065X.2010.00977.x.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273–85. doi:10.1016/j.jhep.2010.09.040.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Deming P, Martin MT, Chan J, Dilworth TJ, El-Lababidi R, Love BL, et al. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2016;36(2):203–17. doi:10.1002/phar.1700.

    PubMed  Article  Google Scholar 

  20. 20.

    Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996;93(26):15394–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol. 1999;162(11):6681–9.

    CAS  PubMed  Google Scholar 

  22. 22.

    Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis. 2004;189(10):1846–55. doi:10.1086/383279.

    PubMed  Article  Google Scholar 

  23. 23.

    Freeman AJ, Ffrench RA, Post JJ, Harvey CE, Gilmour SJ, White PA, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis. 2004;190(6):1093–7. doi:10.1086/422605.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Al-Sherbiny M, Osman A, Mohamed N, Shata MT, Abdel-Aziz F, Abdel-Hamid M, et al. Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg. 2005;73(1):44–9.

    PubMed  Google Scholar 

  25. 25.

    Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis. 2008;198(2):203–12. doi:10.1086/589510.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Zeremski M, Shu MA, Brown Q, Wu Y, Des Jarlais DC, Busch MP, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat. 2009;16(1):10–20. doi:10.1111/j.1365-2893.2008.01016.x.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol. 2004;78(22):12252–8. doi:10.1128/JVI.78.22.12252-12258.2004.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Kubitschke A, Bahr MJ, Aslan N, Bader C, Tillmann HL, Sarrazin C, et al. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest. 2007;37(1):54–64. doi:10.1111/j.1365-2362.2007.01753.x.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Abdelwahab SF, Zakaria Z, Sobhy M, Rewisha E, Mahmoud MA, Amer MA, et al. Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection. Clin Vaccine Immunol. 2012;19(5):780–6. doi:10.1128/CVI.00050-12.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Biceroglu SU, Turhan A, Doskaya AD, Yamazhan T, Donmez A, Altuglu I, et al. Probable hepatitis C virus transmission from a seronegative blood donor via cellular blood products. Blood Transfus. 2014;1:s69–70. doi:10.2450/2013.0285-12.

    Google Scholar 

  31. 31.

    Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–8. doi:10.1038/35099560.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Tanabe M, Kurita-Taniguchi M, Takeuchi K, Takeda M, Ayata M, Ogura H, et al. Mechanism of up-regulation of human Toll-like receptor 3 secondary to infection of measles virus-attenuated strains. Biochem Biophys Res Commun. 2003;311(1):39–48.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Wang C, Pflugheber J, Sumpter Jr R, Sodora DL, Hui D, Sen GC, et al. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol. 2003;77(7):3898–912.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264(5167):1918–21.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Dupuis S, Jouanguy E, Al-Hajjar S, Fieschi C, Al-Mohsen IZ, Al-Jumaah S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet. 2003;33(3):388–91. doi:10.1038/ng1097.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol. 2001;75(15):7059–66. doi:10.1128/JVI.75.15.7059-7066.2001.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol. 2003;77(2):862–70.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  38. 38.

    Afdhal NH. The natural history of hepatitis C. Semin Liver Dis. 2004;24 Suppl 2:3–8. doi:10.1055/s-2004-832922.

    PubMed  Article  Google Scholar 

  39. 39.

    Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61(1S):S14–25. doi:10.1016/j.jhep.2014.06.035.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines. 2011;10(5):659–72. doi:10.1586/erv.11.55.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  41. 41.

    Spaan M, Janssen HL, Boonstra A. Immunology of hepatitis C virus infections. Best Pract Res Clin Gastroenterol. 2012;26(4):391–400. doi:10.1016/j.bpg.2012.09.005.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000;191(9):1499–512.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology. 2006;43(3):563–72. doi:10.1002/hep.21049.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Folgori A, Spada E, Pezzanera M, Ruggeri L, Mele A, Garbuglia AR, et al. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut. 2006;55(7):1012–9. doi:10.1136/gut.2005.080077.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42(1):104–12. doi:10.1002/hep.20749.

    PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1070–83.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39(6):1721–31. doi:10.1002/hep.20266.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Lauer GM, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol. 2005;79(20):12979–88. doi:10.1128/JVI.79.20.12979-12988.2005.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  49. 49.

    Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, Alter H, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40(1):87–97. doi:10.1002/hep.20253.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Abdel-Hakeem MS, Bedard N, Badr G, Ostrowski M, Sekaly RP, Bruneau J, et al. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol. 2010;84(19):10429–35. doi:10.1128/JVI.01094-10.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med. 2012;209(1):61–75. doi:10.1084/jem.20100388.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Badr G, Bedard N, Abdel-Hakeem MS, Trautmann L, Willems B, Villeneuve JP, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol. 2008;82(20):10017–31. doi:10.1128/JVI.01083-08.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Callendret B, Eccleston HB, Hall S, Satterfield W, Capone S, Folgori A, et al. T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology. 2014;60(5):1531–40. doi:10.1002/hep.27278.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A. 2002;99(24):15661–8. doi:10.1073/pnas.202608299.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995;346(8981):1006–7.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C, et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest. 1996;98(3):706–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999;117(4):933–41.

    CAS  PubMed  Article  Google Scholar 

  58. 58.

    Rosen HR, Miner C, Sasaki AW, Lewinsohn DM, Conrad AJ, Bakke A, et al. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: correlation with clinical disease stages. Hepatology. 2002;35(1):190–8. doi:10.1053/jhep.2002.30293.

    PubMed  Article  Google Scholar 

  59. 59.

    Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, Sacchelli L, et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology. 2006;44(1):126–39. doi:10.1002/hep.21242.

    CAS  PubMed  Article  Google Scholar 

  60. 60.

    Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology. 1997;25(2):449–58.

    CAS  PubMed  Article  Google Scholar 

  61. 61.

    Eckels DD, Wang H, Bian TH, Tabatabai N, Gill JC. Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev. 2000;174:90–7.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Godkin A, Jeanguet N, Thursz M, Openshaw P, Thomas H. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. Eur J Immunol. 2001;31(5):1438–46. doi:10.1002/1521-4141(200105)31:5<1438::AID-IMMU1438>3.0.CO;2-2.

    CAS  PubMed  Article  Google Scholar 

  63. 63.

    Sreenarasimhaiah J, Jaramillo A, Crippin J, Lisker-Melman M, Chapman WC, Mohanakumar T. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Hum Immunol. 2003;64(5):497–504.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology. 1996;24(1):6–9. doi:10.1002/hep.510240102.

    CAS  PubMed  Article  Google Scholar 

  65. 65.

    Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002;76(24):12584–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Petrovic D, Dempsey E, Doherty DG, Kelleher D, Long A. Hepatitis C virus--T-cell responses and viral escape mutations. Eur J Immunol. 2012;42(1):17–26. doi:10.1002/eji.201141593.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Jo J, Aichele U, Kersting N, Klein R, Aichele P, Bisse E, et al. Analysis of CD8+ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. Gastroenterology. 2009;136(4):1391–401. doi:10.1053/j.gastro.2008.12.034.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 1999;10(4):439–49.

    CAS  PubMed  Article  Google Scholar 

  69. 69.

    Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med. 2005;201(11):1741–52. doi:10.1084/jem.20050121.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Cucchiarini M, Kammer AR, Grabscheid B, Diepolder HM, Gerlach TJ, Gruner N, et al. Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cell Immunol. 2000;203(2):111–23. doi:10.1006/cimm.2000.1683.

    CAS  PubMed  Article  Google Scholar 

  71. 71.

    Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194(10):1395–406.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. 72.

    Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004;127(3):924–36.

    CAS  PubMed  Article  Google Scholar 

  73. 73.

    Hartling HJ, Gaardbo JC, Ronit A, Knudsen LS, Ullum H, Vainer B, et al. CD4(+) and CD8(+) regulatory T cells (Tregs) are elevated and display an active phenotype in patients with chronic HCV mono-infection and HIV/HCV co-infection. Scand J Immunol. 2012;76(3):294–305. doi:10.1111/j.1365-3083.2012.02725.x.

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    Bolacchi F, Sinistro A, Ciaprini C, Demin F, Capozzi M, Carducci FC, Drapeau CMJ, Rocchi G, Bergamini A. Increased hepatitis C virus (HCV)-specific CD4 + CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol. 2006;144(2):88–196.

    Article  CAS  Google Scholar 

  75. 75.

    Sturm N, Thelu MA, Camous X, Dimitrov G, Ramzan M, Dufeu-Duchesne T, et al. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol. 2010;53(1):25–35. doi:10.1016/j.jhep.2010.02.024.

    CAS  PubMed  Article  Google Scholar 

  76. 76.

    Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol. 2005;79(12):7852–9. doi:10.1128/jvi.79.12.7852-7859.2005.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, et al. T cells with a CD4 + CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol. 2005;79(12):7860–7. doi:10.1128/jvi.79.12.7860-7867.2005.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Itose I, Kanto T, Kakita N, Takebe S, Inoue M, Higashitani K, et al. Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis. J Viral Hepat. 2009;16(12):844–52. doi:10.1111/j.1365-2893.2009.01131.x.

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    Amoroso A, D'Amico F, Consolo M, Skarmoutsou E, Neri S, Dianzani U, et al. Evaluation of circulating CD4 + CD25+ and liver-infiltrating Foxp3+ cells in HCV-associated liver disease. Int J Mol Med. 2012;29(6):983–8. doi:10.3892/ijmm.2012.947.

    CAS  PubMed  Google Scholar 

  80. 80.

    Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology. 2003;38(6):1437–48. doi:10.1016/j.hep.2003.09.026.

    PubMed  Google Scholar 

  81. 81.

    Ward SM, Fox BC, Brown PJ, Worthington J, Fox SB, Chapman RW, et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol. 2007;47(3):316–24. doi:10.1016/j.jhep.2007.03.023.

    CAS  PubMed  Article  Google Scholar 

  82. 82.

    Keynan Y, Card CM, McLaren PJ, Dawood MR, Kasper K, Fowke KR. The role of regulatory T cells in chronic and acute viral infections. Clin Infect Dis. 2008;46(7):1046–52. doi:10.1086/529379.

    PubMed  Article  Google Scholar 

  83. 83.

    Lanphear BP, Linnemann Jr CC, Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in healthcare workers: risk of exposure and infection. Infect Control Hosp Epidemiol. 1994;15(12):745–50.

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    Kosgeroglu N, Ayranci U, Vardareli E, Dincer S. Occupational exposure to hepatitis infection among Turkish nurses: frequency of needle exposure, sharps injuries and vaccination. Epidemiol Infect. 2004;132(1):27–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Hofmann F, Michaelis M, Rieger MA, Hasselhorn HM, Berthold H. Occupational medicine significance of hepatitis C in health care employees. Gesundheitswesen. 1997;59(7):452–60.

    CAS  PubMed  Google Scholar 

  86. 86.

    Baldo V, Floreani A, Dal Vecchio L, Cristofoletti M, Carletti M, Majori S, et al. Occupational risk of blood-borne viruses in healthcare workers: a 5-year surveillance program. Infect Control Hosp Epidemiol. 2002;23(6):325–7. doi:10.1086/502059.

    PubMed  Article  Google Scholar 

  87. 87.

    Thorburn D, Roy K, Cameron SO, Johnston J, Hutchinson S, McCruden EA, et al. Risk of hepatitis C virus transmission from patients to surgeons: model based on an unlinked anonymous study of hepatitis C virus prevalence in hospital patients in Glasgow. Gut. 2003;52(9):1333–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  88. 88.

    Hashem M, El-Karaksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, et al. Strong hepatitis C virus (HCV)-specific cell-mediated immune responses in the absence of viremia or antibodies among uninfected siblings of HCV chronically infected children. J Infect Dis. 2011;203(6):854–61. doi:10.1093/infdis/jiq123.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  89. 89.

    Perrella A, Grattacaso S, d'Antonio A, Atripaldi L, Sbreglia C, Gnarini M, et al. Evidence of hepatitis C virus-specific interferon gamma-positive T cells in health care workers in an infectious disease department. Am J Infect Control. 2009;37(5):426–9. doi:10.1016/j.ajic.2008.08.003.

    PubMed  Article  Google Scholar 

  90. 90.

    Abdelwahab SF, Hashem M, Galal I, Sobhy M, Abdel-Ghaffar TS, Galal G et al. Incidence of hepatitis C virus infection among Egyptian healthcare workers at high risk of infection. J Clinical Virology. 2013. doi:10.1016/j.jcv.2013.01.005.

  91. 91.

    Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis. 1997;176(4):859–66.

    CAS  PubMed  Article  Google Scholar 

  92. 92.

    Roque-Cuellar MC, Sanchez B, Garcia-Lozano JR, Praena-Fernandez JM, Nunez-Roldan A, Aguilar-Reina J. Cellular immune responses and occult infection in seronegative heterosexual partners of chronic hepatitis C patients. J Viral Hepat. 2011;18(10):e541–9. doi:10.1111/j.1365-2893.2011.01464.x.

    CAS  PubMed  Article  Google Scholar 

  93. 93.

    Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, et al. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J. 2007;4:58. doi:10.1186/1743-422X-4-58.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  94. 94.

    Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis. 2013;56(3):405–13. doi:10.1093/cid/cis921.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Shata MT, Tricoche N, Perkus M, Tom D, Brotman B, McCormack P, et al. Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees. Virology. 2003;314(2):601–16.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med. 2013;19(12):1638–42. doi:10.1038/nm.3408.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  97. 97.

    Munier A, Marzouk D, Abravanel F, El-Daly M, Taylor S, Mamdouh R, et al. Frequent transient hepatitis C viremia without seroconversion among healthcare workers in Cairo, Egypt. PLoS ONE. 2013;8(2):e57835. doi:10.1371/journal.pone.0057835.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Abdelwahab SF, Zakaria Z, Sobhy M, Hamdy S, Mahmoud MA, Mikhail N, et al. Differential distribution of IL28B.rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response. Arch Virol. 2015;160(7):1741–50. doi:10.1007/s00705-015-2446-7.

    CAS  PubMed  Article  Google Scholar 

  99. 99.

    El-Kamary SS, Hashem M, Saleh DA, Abdelwahab SF, Sobhy M, Shebl FM, et al. Hepatitis C virus-specific cell-mediated immune responses in children born to mothers infected with hepatitis C virus. J Pediatr. 2013;162(1):148–54. doi:10.1016/j.jpeds.2012.06.057.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Rafik MM, Hosny Ael D, Abdallah KO, Abbas AA, Abo Shady RA, Soliman DA, et al. TH1 cytokine response to HCV peptides in Egyptian health care workers: a pilot study. Virol J. 2013;10:144. doi:10.1186/1743-422X-10-144.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  101. 101.

    Penna A, Missale G, Lamonaca V, Pilli M, Mori C, Zanelli P, et al. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology. 2002;35(5):1225–36. doi:10.1053/jhep.2002.33153.

    CAS  PubMed  Article  Google Scholar 

  102. 102.

    Januszkiewicz-Lewandowska D, Wysocki J, Rembowska J, Pernak M, Lewandowski K, Nowak T, et al. Transmission of HCV infection among long-term hospitalized onco-haematological patients. J Hosp Infect. 2003;53(2):120–3.

    CAS  PubMed  Article  Google Scholar 

  103. 103.

    Makary MA, Al-Attar A, Holzmueller CG, Sexton JB, Syin D, Gilson MM, et al. Needlestick injuries among surgeons in training. N Engl J Med. 2007;356(26):2693–9. doi:10.1056/NEJMoa070378.

    CAS  PubMed  Article  Google Scholar 

  104. 104.

    Mizuno Y, Suzuki K, Mori M, Hayashi K, Owaki T, Hayashi H, et al. Study of needlestick accidents and hepatitis C virus infection in healthcare workers by molecular evolutionary analysis. J Hosp Infect. 1997;35(2):149–54.

    CAS  PubMed  Article  Google Scholar 

  105. 105.

    Quer J, Esteban JI, Sanchez JM, Otero T, Rius C, Coll M, et al. Nosocomial transmission of hepatitis C virus during contrast-enhanced computed tomography scanning. Eur J Gastroenterol Hepatol. 2008;20(1):73–8. doi:10.1097/MEG.0b013e32825b07b0.

    PubMed  Article  Google Scholar 

  106. 106.

    Kaul R, Rutherford J, Rowland-Jones SL, Kimani J, Onyango JI, Fowke K, et al. HIV-1 Env-specific cytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: a prospective analysis. AIDS. 2004;18(15):2087–9.

    PubMed  Article  Google Scholar 

  107. 107.

    Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995;74(4):212–20.

    CAS  PubMed  Article  Google Scholar 

  108. 108.

    Riviere Y, Montange T, Janvier G, Marnata C, Durrieu L, Chaix ML, et al. Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection. Virol J. 2012;9:76. doi:10.1186/1743-422X-9-76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  109. 109.

    Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, et al. Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008;198(12):1749–55. doi:10.1086/593337.

    PubMed  Article  Google Scholar 

  110. 110.

    Thurairajah PH, Hegazy D, Demaine A, Kaminski ER, Cramp ME. Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation. J Infect Dis. 2011;203(6):847–53. doi:10.1093/infdis/jiq121.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  111. 111.

    Choi YS, Lee JE, Nam SJ, Park JT, Kim HS, Choi KH, et al. Two Distinct Functional Patterns of Hepatitis C Virus (HCV)-Specific T Cell Responses in Seronegative, Aviremic Patients. PLoS ONE. 2013;8(4), e62319. doi:10.1371/journal.pone.0062319.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  112. 112.

    Quiroga JA, Llorente S, Castillo I, Rodriguez-Inigo E, Pardo M, Carreno V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol. 2006;80(22):10972–9. doi:10.1128/JVI.00852-06.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  113. 113.

    Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology. 2009;49(2):665–75. doi:10.1002/hep.22706.

    PubMed  Article  Google Scholar 

  114. 114.

    Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215–29. doi:10.1038/nri1573.

    CAS  PubMed  Article  Google Scholar 

  115. 115.

    Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol. 2001;75(23):11392–400. doi:10.1128/JVI.75.23.11392-11400.2001.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  116. 116.

    Yasukawa M, Yakushijin Y, Furukawa M, Fujita S. Specificity analysis of human CD4+ T-cell clones directed against human herpesvirus 6 (HHV-6), HHV-7, and human cytomegalovirus. J Virol. 1993;67(10):6259–64.

    CAS  PubMed  PubMed Central  Google Scholar 

  117. 117.

    Kennedy PT, Urbani S, Moses RA, Amadei B, Fisicaro P, Lloyd J, et al. The influence of T cell cross-reactivity on HCV-peptide specific human T cell response. Hepatology. 2006;43(3):602–11. doi:10.1002/hep.21081.

    CAS  PubMed  Article  Google Scholar 

  118. 118.

    Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol. 2003;77(8):4781–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Acknowledgements

Thanks are due to American Journal Experts for editing the manuscript for proper English, grammar, punctuation, spelling and style. Thanks are also due for Dr. Gamal Allam, Professor of Immunology, College of Medicine, Taif University for proof editing the manuscript.

Author information

Affiliations

  1. Departement of Microbiology and Immunology, Faculty of Medicine, Minia University, Minia, 61511, Egypt

    Sayed F. Abdelwahab

  2. Department of Microbiology, College of Pharmacy, Taif University, Taif, 21974, Kingdom of Saudi Arabia

    Sayed F. Abdelwahab

Authors
  1. Sayed F. Abdelwahab
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sayed F. Abdelwahab.

Additional information

Competing interests

The author declares that he/she has no competing interests.

Authors' contributions

A, SF solely contributed to this paper.

Authors’ information

Dr Abdelwahab is currently a professor at Minia Faculty of Medicine (Egypt) and at Taif University College of Pharmacy (KSA). He obtained a Pharmacy degree from Assiut University in 1989 and completed his PhD in Immunology at the University of Maryland School of Medicine in 2002. Dr Abdelwahab research interests include cellular immunity to viruses including HCV, HIV and HEV and he has published 39 papers in international journals and 11 papers in local Egyptian journals. He supervised 26 Master's and PhD students and attended ~75 international conferences.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abdelwahab, S.F. Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?. Infect Agents Cancer 11, 23 (2016). https://doi.org/10.1186/s13027-016-0070-0

Download citation

Keywords

  • Cell-mediated immunity
  • CD4 T cells
  • CD8 T cells
  • Hepatitis C virus
  • Healthcare workers
  • Interferon-γ
  • IVDU
  • T-cells
  • Viral hepatitis
  • Vaccines

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us